DGX Quest Diagnostics Incorporated Common Stock
$240,04
Prezzo · Ago 19, 2026
Fondamentali al Lug 23, 2026
Intervallo 52 sett.
$171–$242
97% of range
Rating Analisti
HOLD
23 analysts
Prezzo Obiettivo
$246
+2% upside
P/E (TTM)
27.7
ROE
14.2%
Margine di Profitto Netto
9.0%
Informazioni su Quest Diagnostics Incorporated Common Stock Panoramica della società da Wikipedia
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Leggi di più
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
As of 2020, the company had approximately 48,000 employees, and it generated more than $7.7 billion in revenue in 2019. The company offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, COVID-19, and employment and court-ordered drug testing.
History
1960–1995
Originally founded as Metropolitan Pathology Laboratory, Inc. in 1967 by Paul A. Brown, MD, the clinical laboratory underwent a variety of name changes. In 1969, the company's name changed to MetPath, Inc. with headquarters in Teaneck, New Jersey. By 1982, MetPath was acquired by what was then known as Corning Glass Works and was subsequently renamed Corning Clinical Laboratories.
1996–2000
On December 31, 1996, Quest Diagnostics became an independent company as a spin-off from Corning. Kenneth W. Freeman was appointed as CEO during this transition. Over the next year, Quest acquired a clinical laboratory division of Branford, Connecticut–based Diagnostic Medical Laboratory, Inc. (DML). Two years later in 1999, Quest added SmithKline Beecham Clinical Laboratories to their subsidiaries; which includes a joint venture ownership with CompuNet Clinical Laboratory. The purchase of SmithKline Beecham also included the lab's medical sample transport airline (ICAO: LBQ, call sign: LABQUEST) originally founded in 1988.
In 1997, Quest and Banner Health formed a joint venture creating the Arizona based Sonora Quest laboratory, a business unit of Laboratory Sciences of Arizona. This entity represents the operations of Quest Diagnostics in the Arizona regional market.
2001–2015
From May 2004 to April 2012, Surya Mohapatra served as the company's President and CEO. In 2007 Quest acquired diagnostic testing equipment company AmeriPath. In response to Mohapatra's resignation after eight years with Quest, former Philips Healthcare CEO Stephen Rusckowski was appointed. Under Rusckowski, Quest Diagnostics teamed up with central New England's largest health care system, UMass Memorial Health Care, to purchase its clinical outreach laboratory.
2016–present
In 2016, Quest collaborated with Safeway to bring testing services to twelve of its stores in California, Maryland, Virginia, Texas and Colorado.
By the end of 2017, Quest, in partnership with Walmart, incorporated laboratory testing in about 15 of their locations in Texas and Florida.
In May 2018, the company announced it will become an in-network laboratory provider to UnitedHealthcare starting in 2019, providing access to 48 million plan members.
In September 2018, Quest moved its headquarters from Madison, where it was located since 2007, to Secaucus, New Jersey.
In November 2018, Quest launched QuestDirect, a consumer-initiated testing service that allows patients to order health and wellness lab testing from home.
In March 2020, the company launched a COVID-19 testing service. As of July 2020, Quest had performed more than 9.2 million COVID-19 molecular tests and 2.8 million serology tests.
In April 2024, Quest has added a new blood screening to their AD-Detect product line. This test will analyze the blood for a specific Alzheimer's protein, pTau-217.
In February 2025, Quest acquired select assets of Fresenius Medical Care's Spectra laboratories. Under a separate agreement, Quest now offers clinical testing and lab services related to dialysis and end-stage kidney disease.
Acquisitions
Partnerships
2005: Forms a strategic alliance with Ciphergen Biosystems to commercialize novel proteomic tests.
Controversies
Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical laboratory for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state's Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs.
In 2018, Quest Diagnostics was among a number of U.S.–based laboratories linked to inaccuracies of over 200 women's cervical smear tests for CervicalCheck, Ireland's national screening program. Audits of the testing performed by Quest (and another subcontractor, Clinical Pathology Laboratories, Inc. of Austin, Texas) showed a high rate of errors in analysis of samples which led to lawsuits and a government inquiry. Quest and the Irish government continue to settle the resulting lawsuits.
On June 3, 2019, Quest announced that American Medical Collection Agency (AMCA), a billing collections service provider, had informed Quest Diagnostics that an unauthorized user had access to AMCA’s system containing personal information AMCA received from various entities, including from Quest. AMCA provides billing collections services to Optum360, which in turn is a Quest contractor. AMCA later went bankrupt after the breach.
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
DGX Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$240.04
Capitalizzazione di Mercato
$26.64B
P/E (TTM)
27.7
EPS (TTM)
$8.75
Ricavi (TTM)
$11.04B
Rendimento div.
1.3%
ROE
14.2%
D/E Debito/Patrimonio
0.8
Intervallo 52 sett.
$171 – $242
DGX Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
Configure
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi e Utile Netto
$11.04B
2016-12-31
→
2025-12-31
EPS
$8.75
2016-12-31
→
2025-12-31
Flusso di cassa libero
$1.36B
2016-12-31
→
2025-12-31
Margini
9.0%
2016-12-31
→
2020-12-31
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
Metrica
Tendenza 5 anni
DGX
Mediana dei peer
P/E (TTM)
27.7
26.5
P/S (TTM)
2.4
2.0
P/B
3.7
4.9
EV / EBITDA
15.0
—
Price / FCF (Prezzo / FCF)
19.6
—
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
Metrica
Tendenza 5 anni
DGX
Mediana dei peer
Operating Margin (Margine Operativo)
14.1%
—
Net Profit Margin (Margine di Profitto Netto)
9.0%
4.0%
ROA
6.1%
5.0%
ROE
14.2%
15.2%
ROIC
9.2%
—
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
Metrica
Tendenza 5 anni
DGX
Mediana dei peer
Debt / Equity (Debito / Patrimonio Netto)
0.8
—
Current Ratio (Rapporto corrente)
1.0
1.6
Quick Ratio
0.8
—
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Metrica
Tendenza 5 anni
DGX
Mediana dei peer
Revenue YoY (Ricavi YoY)
11.8%
—
Revenue CAGR 3Y (CAGR Ricavi 3Y)
3.7%
—
Revenue CAGR 5Y (CAGR Ricavi 5Y)
3.2%
—
EPS YoY
13.8%
—
Net Income YoY (Utile Netto YoY)
13.9%
—
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Metrica
Tendenza 5 anni
DGX
Mediana dei peer
Payout Ratio (Rapporto di Distribuzione Utili)
35.6%
—
Dividendi Rendimento, payout ratio, storico dividendi, CAGR 5Y
Dividend Yield
1.3%
Rapporto di Distribuzione Utili
35.6%
CAGR Dividendi 5Y
—
| Data ex-dividendo | Importo |
|---|---|
| 08 Luglio 2026 | $0,8600 |
| 06 Aprile 2026 | $0,8600 |
| 13 Gennaio 2026 | $0,8000 |
| 03 Ottobre 2025 | $0,8000 |
| 07 Luglio 2025 | $0,8000 |
| 07 Aprile 2025 | $0,8000 |
| 14 Gennaio 2025 | $0,7500 |
| 04 Ottobre 2024 | $0,7500 |
| 08 Luglio 2024 | $0,7500 |
| 05 Aprile 2024 | $0,7500 |
| 16 Gennaio 2024 | $0,7100 |
| 05 Ottobre 2023 | $0,7100 |
| 10 Luglio 2023 | $0,7100 |
| 06 Aprile 2023 | $0,7100 |
| 17 Gennaio 2023 | $0,6600 |
| 03 Ottobre 2022 | $0,6600 |
| 05 Luglio 2022 | $0,6600 |
| 05 Aprile 2022 | $0,6600 |
| 18 Gennaio 2022 | $0,6200 |
| 04 Ottobre 2021 | $0,6200 |
DGX Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
COMPRA
23 analisti
- Acquisto forte 6 26,1%
- Compra 7 30,4%
- Mantieni 10 43,5%
- Vendi 0 0,0%
- Vendita forte 0 0,0%
Target Price a 12 Mesi
15 analisti · 2026-08-16
Mediana
$250.00
Ora
$240.04
Basso
$204.00
Alto
$265.00
Target mediano
$250.00
+4,1%
Target medio
$245.87
+2,4%
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
0.09%
| Periodo | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|
| 30 Giugno 2026 | $3.12 | $2.85 | 0.27% |
| 31 Marzo 2026 | $2.50 | $2.37 | 0.13% |
| 31 Dicembre 2025 | $2.42 | $2.38 | 0.04% |
| 30 Settembre 2025 | $2.60 | $2.53 | 0.07% |
| 30 Giugno 2025 | $2.62 | $2.60 | 0.02% |
| 31 Marzo 2025 | $2.21 | $2.17 | 0.04% |
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| DGX | $19.09B | 19.8 | 11.8% | 9.0% | 14.2% | — |
| CVS | $100.87B | 57.1 | 7.8% | 0.44% | 2.4% | — |
| CI | $72.51B | 12.4 | 11.2% | 2.2% | 14.4% | — |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| GH | $13.34B | -30.8 | 32.9% | -42.4% | 205.7% | — |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| BTSG | $7.20B | 43.0 | 28.2% | 1.5% | 10.8% | 11.8% |
| DVA | $7.79B | 11.5 | 6.5% | 5.5% | -281.8% | — |
| HNGE | $0 | -6.0 | 50.6% | -89.9% | -299.8% | 79.7% |
| CHE | — | 23.3 | 4.1% | 10.5% | 24.4% | — |
| HIMS | — | 63.7 | 59.0% | 5.5% | 23.3% | 73.8% |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico 17
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Cost of Revenue | $7.37B | $6.63B | $6.20B | $6.45B | $6.58B | $5.80B | $5.04B | $4.93B | $4.72B | $4.62B | $4.66B | $4.64B | |
| Gross Profit | · | · | · | · | · | $3.63B | $2.69B | $2.60B | $2.68B | $2.90B | $2.84B | $2.80B | |
| SG&A Expense | $1.97B | $1.77B | $1.64B | $1.87B | $1.73B | $1.55B | $1.46B | $1.42B | $1.44B | $1.38B | $1.68B | $1.73B | |
| Operating Expenses | $9.48B | $8.53B | $7.99B | $8.46B | $8.41B | $7.47B | $6.50B | $6.43B | $6.24B | $5.94B | $6.09B | $6.45B | |
| Operating Income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B | $1.23B | $1.10B | $1.17B | $1.28B | $1.40B | $983M | |
| Interest Expense | · | · | $163M | $148M | $152M | $166M | $180M | $169M | $153M | $144M | $154M | $167M | |
| Interest Income | $13M | $25M | $11M | $10M | $1M | $3M | $5M | $2M | $2M | $1M | $1M | $3M | |
| Other Non-op | $26M | $30M | $20M | $-55M | $369M | $76M | $20M | $-8M | $16M | $-48M | $-143M | $4M | |
| Pretax Income | $1.32B | $1.18B | $1.13B | $1.24B | $2.60B | $1.88B | $1.08B | $926M | $1.03B | $1.09B | $1.10B | $823M | |
| Income Tax | $314M | $273M | $248M | $264M | $597M | $460M | $247M | $182M | $241M | $429M | $373M | $262M | |
| Net Income | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| EPS (Basic) | $8.87 | $7.78 | $7.59 | $8.10 | $15.85 | $10.62 | $6.36 | $5.39 | $5.63 | $4.58 | $4.92 | $3.83 | |
| EPS (Diluted) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 | |
| Shares (Basic) | 111,000,000 | 111,000,000 | 112,000,000 | 116,000,000 | 125,000,000 | 134,000,000 | 134,000,000 | 136,000,000 | 137,000,000 | 140,000,000 | 144,000,000 | 145,000,000 | |
| Shares (Diluted) | 113,000,000 | 113,000,000 | 113,000,000 | 118,000,000 | 128,000,000 | 136,000,000 | 136,000,000 | 139,000,000 | 140,000,000 | 142,000,000 | 145,000,000 | 145,000,000 | |
| EBITDA | $2.13B | $1.84B | $1.70B | $1.86B | $2.79B | $2.33B | $1.56B | $1.41B | $1.44B | $1.53B | $1.70B | $1.30B |
Stato Patrimoniale 27
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $420M | $549M | $686M | $315M | $872M | $1.16B | $1.19B | $135M | $137M | $359M | $133M | $192M | |
| Receivables | $1.41B | $1.30B | $1.21B | $1.20B | $1.44B | $1.52B | $1.06B | $1.01B | $924M | $926M | $901M | $932M | |
| Inventory | $189M | $188M | $190M | $192M | $208M | $223M | $123M | $99M | $95M | $82M | $84M | $110M | |
| Prepaid Expense | $361M | $351M | $286M | $196M | $223M | $157M | $112M | $144M | $150M | $155M | $207M | $186M | |
| Current Assets | $2.38B | $2.39B | $2.37B | $1.90B | $2.74B | $3.06B | $2.49B | $1.39B | $1.31B | $1.53B | $1.50B | $1.60B | |
| PP&E (Net) | $2.20B | $2.11B | $1.82B | $1.77B | $1.71B | $1.63B | $1.45B | $1.29B | $1.15B | $1.03B | $925M | $933M | |
| PP&E (Gross) | $6.18B | $5.77B | $5.23B | $5.10B | $4.79B | $4.62B | $4.23B | $3.97B | $3.67B | $3.43B | $3.23B | $3.13B | |
| Accum. Depreciation | $3.97B | $3.66B | $3.42B | $3.34B | $3.09B | $2.99B | $2.78B | $2.68B | $2.53B | $2.40B | $2.31B | $2.19B | |
| Goodwill | $8.95B | $8.86B | $7.73B | $7.22B | $7.09B | $6.87B | $6.62B | $6.56B | $6.33B | $6.00B | $5.91B | $6.03B | |
| Intangibles | $1.64B | $1.76B | $1.17B | $1.09B | $1.17B | $1.17B | $1.12B | $1.21B | $1.12B | $949M | $984M | $1.07B | |
| Other Non-current Assets | $270M | $255M | $198M | $144M | $163M | $176M | $160M | $119M | $136M | $148M | $174M | $172M | |
| Total Assets | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Accounts Payable | $1.60B | $1.39B | $1.36B | $1.40B | $1.60B | $1.63B | $1.04B | $1.02B | $1.02B | $975M | $1.01B | $1.19B | |
| Accrued Liabilities | $338M | $306M | $287M | $392M | $460M | $356M | $223M | $274M | $246M | $254M | $257M | $277M | |
| Current Liabilities | $2.28B | $2.17B | $1.81B | $1.55B | $1.75B | $1.78B | $1.99B | $1.49B | $1.06B | $981M | $1.17B | $1.71B | |
| Capital Leases | $537M | $535M | $503M | $489M | $494M | $499M | $413M | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $264M | $243M | $170M | $191M | $157M | $204M | |
| Other Non-current Liabilities | $957M | $938M | $876M | $812M | $792M | $847M | $711M | $745M | $663M | $654M | $514M | $594M | |
| Long-term Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.74B | |
| Total Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.76B | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Retained Earnings | $9.99B | $9.36B | $8.82B | $8.29B | $7.65B | $9.30B | $8.17B | $7.60B | $7.14B | $6.61B | $6.20B | $5.72B | |
| Treasury Stock | $5.18B | $4.86B | $4.83B | $4.67B | $3.45B | $5.37B | $5.22B | $5.00B | $4.78B | $4.46B | $3.96B | $3.81B | |
| AOCI | $-27M | $-88M | $-14M | $-21M | $-14M | $-21M | $-39M | $-59M | $-48M | $-72M | $-38M | $-27M | |
| Stockholders' Equity | $7.17B | $6.78B | $6.31B | $5.89B | $6.44B | $6.76B | $5.64B | $5.22B | $4.92B | $4.63B | $4.68B | $4.30B | |
| Liabilities + Equity | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 119,000,000 | 133,000,000 | 133,000,000 | 135,000,000 | 135,000,000 | 137,000,000 | 143,000,000 | 144,000,000 |
Flusso di cassa 17
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $570M | $493M | $439M | $437M | $408M | $361M | $329M | $309M | $270M | $249M | $304M | $314M | |
| Stock-based Comp | $88M | $88M | $77M | $77M | $79M | $97M | $56M | $61M | $79M | $69M | $52M | $51M | |
| Deferred Tax | $105M | $13M | $-49M | $1M | $-57M | $85M | $15M | $73M | $9M | $37M | $112M | $23M | |
| Amort. of Intangibles | $154M | $127M | $108M | $120M | $103M | $103M | $96M | $90M | $74M | $72M | $81M | $94M | |
| Restructuring | · | · | · | $55M | $13M | $14M | $-3M | $49M | $30M | $11M | $39M | $43M | |
| Other Non-cash | $131M | $-131M | $-49M | $257M | $-192M | $31M | $-15M | $21M | $45M | $69M | $-367M | $-6M | |
| Operating Cash Flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B | $2.00B | $1.24B | $1.20B | $1.18B | $1.12B | $821M | $944M | |
| CapEx | $527M | $425M | $408M | $404M | $403M | $418M | $400M | $383M | $252M | $293M | $263M | $308M | |
| Investing Cash Flow | $-631M | $-2.55B | $-1.06B | $-543M | $21M | $-772M | $-411M | $-801M | $-830M | $-127M | $-362M | $-1.02B | |
| Stock Repurchased | $450M | $151M | $275M | $1.41B | $2.20B | $325M | $353M | $322M | $465M | $590M | $224M | $132M | |
| Net Stock Activity | $-450M | $-151M | $-275M | $-1.41B | $-2.20B | $-325M | $-353M | $-322M | $-465M | $-590M | $-224M | $-132M | |
| Dividends Paid | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M | |
| Financing Cash Flow | $-1.39B | $1.08B | $160M | $-1.73B | $-2.54B | $-1.27B | $225M | $-401M | $-592M | $-738M | $-518M | $86M | |
| Net Change in Cash | $-129M | $-137M | $371M | $-557M | $-286M | · | · | · | $-222M | $226M | $-59M | $5M | |
| Taxes Paid | $169M | $256M | $317M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $1.36B | $909M | $864M | $1.31B | $1.83B | $1.59B | $843M | $817M | $923M | $776M | $547M | $630M | |
| Levered FCF | · | · | $737M | $1.20B | $1.71B | $1.46B | $704M | $681M | $806M | $689M | · | · |
Redditività 8
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 38.5% | 34.8% | 34.6% | 38.8% | 38.6% | 37.9% | 37.6% | |
| Operating Margin | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% | 20.9% | 15.9% | 14.6% | 15.1% | 17.0% | 18.7% | 13.2% | |
| Net Margin | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% | 15.2% | 11.1% | 9.8% | 10.0% | 8.6% | 9.5% | 7.5% | |
| Pretax Margin | 11.9% | 11.9% | 12.2% | 12.5% | 24.1% | 20.0% | 13.9% | 12.3% | 13.4% | 14.4% | 14.7% | · | |
| EBITDA Margin | 19.3% | 18.6% | 18.4% | 18.9% | 25.9% | 24.7% | 20.2% | 18.7% | 18.6% | 20.3% | 22.7% | 17.4% | |
| ROA | 6.1% | 5.8% | 6.4% | 7.1% | 14.4% | 10.7% | 7.2% | 6.8% | 7.5% | 6.4% | 7.1% | 5.9% | |
| ROE | 14.2% | 13.3% | 14.0% | 15.3% | 30.2% | 23.1% | 15.8% | 14.5% | 16.2% | 13.9% | 15.8% | 13.5% | |
| ROIC | 9.2% | 8.0% | 8.9% | 11.4% | 17.5% | 13.8% | 9.1% | 9.7% | 10.2% | 9.2% | 11.1% | · |
Liquidità e Solvibilità 5
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 | 1.7 | 1.3 | 0.9 | 1.2 | 1.6 | 1.3 | 0.9 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 | 1.5 | 1.1 | 0.8 | 1.0 | 1.3 | 0.9 | 0.7 | |
| Debt / Equity | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 | 0.6 | 0.8 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | |
| LT Debt / Equity | 0.7 | 0.8 | 0.7 | 0.7 | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | 0.8 | 0.7 | 0.8 | |
| Interest Coverage | · | · | 7.7 | 9.6 | 15.7 | 11.9 | 6.8 | 6.5 | 7.6 | 8.9 | · | · |
Efficienza 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.8 | 0.8 | |
| Inventory Turnover | 39.1 | 35.1 | 32.5 | 32.2 | 30.5 | 33.5 | 45.4 | 50.8 | 53.3 | 55.6 | 48.0 | 46.1 | |
| Receivables Turnover | 8.1 | 7.9 | 7.7 | 7.5 | 7.3 | 7.3 | 7.4 | 7.8 | 8.3 | 8.2 | 8.2 | 8.3 |
Tassi di Crescita 10
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.8% | 6.7% | -6.4% | -8.4% | 14.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 3.7% | -2.9% | -0.66% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 3.2% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 13.8% | 2.7% | -6.0% | -48.8% | 48.5% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 3.2% | -20.9% | -10.6% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -3.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 13.9% | 2.0% | -9.7% | -52.6% | 39.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 1.6% | -24.1% | -15.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 3.5% | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM) 16
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Net Income TTM | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| Market Cap | $19.09B | $16.75B | $15.30B | $17.36B | $20.59B | $15.85B | $14.20B | $11.24B | $13.30B | $12.59B | $10.17B | $9.66B | |
| Enterprise Value | $24.34B | $22.41B | $19.33B | $21.03B | $23.73B | $18.71B | $17.78B | $15.00B | $16.94B | $15.97B | $13.69B | $13.23B | |
| P/E | 19.8 | 19.6 | 18.4 | 19.6 | 11.1 | 11.4 | 17.0 | 15.7 | 17.9 | 20.4 | 14.6 | 17.6 | |
| P/S | 1.7 | 1.7 | 1.7 | 1.8 | 1.9 | 1.7 | 1.8 | 1.5 | 1.8 | 1.7 | 1.4 | 1.3 | |
| P/B | 2.7 | 2.5 | 2.4 | 2.9 | 3.2 | 2.3 | 2.5 | 2.2 | 2.7 | 2.7 | 2.2 | 2.2 | |
| P / Cash Flow | 10.1 | 12.6 | 12.0 | 10.1 | 9.2 | 7.9 | 11.4 | 9.4 | 11.3 | 11.8 | 12.6 | 10.3 | |
| P / FCF | 14.0 | 18.4 | 17.7 | 13.2 | 11.3 | 10.0 | 16.8 | 13.8 | 14.4 | 16.2 | 18.6 | 15.3 | |
| EV / EBITDA | 11.4 | 12.2 | 11.4 | 11.3 | 8.5 | 8.0 | 11.4 | 10.6 | 11.8 | 10.5 | 8.0 | 10.2 | |
| EV / FCF | 17.9 | 24.7 | 22.4 | 16.0 | 13.0 | 11.8 | 21.1 | 18.4 | 18.4 | 20.6 | 25.0 | 21.0 | |
| EV / Revenue | 2.2 | 2.3 | 2.1 | 2.1 | 2.2 | 2.0 | 2.3 | 2.0 | 2.3 | 2.2 | 1.8 | 1.8 | |
| Dividend Yield | 1.8% | 2.0% | 2.1% | 1.8% | 1.5% | 1.9% | 2.0% | 2.4% | 1.9% | 1.8% | 2.1% | 1.9% | |
| Earnings Yield | 5.0% | 5.1% | 5.4% | 5.1% | 9.0% | 8.8% | 5.9% | 6.3% | 5.6% | 4.9% | 6.9% | 5.7% | |
| Payout Ratio | 35.6% | 38.0% | 36.8% | 32.2% | 15.5% | 20.8% | 33.3% | 36.1% | 32.0% | 34.6% | 29.9% | 33.6% | |
| Annual Payout | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M |
Conto Economico 16
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.04B | $2.90B | $2.81B | $2.82B | $2.76B | $2.65B | $2.62B | $2.49B | $2.40B | $2.37B | $2.29B | $2.29B | $2.34B | $2.33B | $2.33B | $2.49B | |
| Cost of Revenue | $2.02B | $1.95B | $1.90B | $1.87B | $1.82B | $1.79B | $1.76B | $1.68B | $1.59B | $1.59B | $1.55B | $1.54B | $1.55B | $1.56B | $1.57B | $1.62B | |
| SG&A Expense | $529M | $504M | $504M | $501M | $486M | $476M | $466M | $448M | $416M | $440M | $407M | $380M | $416M | $439M | $563M | $464M | |
| Operating Expenses | $2.58B | $2.50B | $2.42B | $2.43B | $2.32B | $2.31B | $2.26B | $2.16B | $2.04B | $2.07B | $2.02B | $1.95B | $1.99B | $2.03B | $2.20B | $2.09B | |
| Operating Income | $459M | $399M | $386M | $386M | $438M | $346M | $361M | $330M | $355M | $300M | $267M | $342M | $348M | $305M | $135M | $392M | |
| Interest Expense | · | · | · | · | · | · | · | · | $47M | $49M | · | $41M | $39M | $37M | · | $37M | |
| Interest Income | $5M | $2M | $3M | $3M | $2M | $5M | $7M | $9M | $3M | $6M | $6M | $1M | $2M | $2M | $4M | $4M | |
| Other Non-op | $16M | $-2M | $8M | $8M | $13M | $-3M | $3M | $15M | $3M | $9M | $10M | $-3M | $6M | $7M | $6M | $-8M | |
| Pretax Income | $412M | $334M | $330M | $328M | $384M | $276M | $299M | $296M | $314M | $266M | $237M | $299M | $317M | $277M | $109M | $351M | |
| Income Tax | $88M | $74M | $81M | $77M | $97M | $59M | $68M | $65M | $74M | $66M | $40M | $68M | $75M | $65M | $-4M | $81M | |
| Net Income | $320M | $252M | $245M | $245M | $282M | $220M | $222M | $226M | $229M | $194M | $192M | $225M | $235M | $202M | $101M | $256M | |
| EPS (Basic) | $2.88 | $2.27 | $2.21 | $2.18 | $2.51 | $1.97 | $1.98 | $2.01 | $2.05 | $1.74 | $1.72 | $1.99 | $2.08 | $1.80 | $0.93 | $2.20 | |
| EPS (Diluted) | $2.84 | $2.24 | $2.18 | $2.16 | $2.47 | $1.94 | $1.95 | $1.99 | $2.03 | $1.72 | $1.70 | $1.96 | $2.05 | $1.78 | $0.92 | $2.17 | |
| Shares (Basic) | 111,000,000 | 110,000,000 | -224,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | -223,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | -224,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | -236,000,000 | 116,000,000 | |
| Shares (Diluted) | 112,000,000 | 112,000,000 | -226,000,000 | 113,000,000 | 113,000,000 | 113,000,000 | -224,000,000 | 113,000,000 | 112,000,000 | 112,000,000 | -228,000,000 | 114,000,000 | 114,000,000 | 113,000,000 | -240,000,000 | 118,000,000 | |
| EBITDA | $605M | $546M | · | $528M | $581M | $486M | · | $455M | $472M | $416M | · | $453M | $460M | $412M | · | $500M |
Stato Patrimoniale 26
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $626M | $393M | $420M | $432M | $319M | $188M | $549M | $764M | $271M | $474M | · | $143M | $126M | $175M | · | $700M | |
| Receivables | $1.67B | $1.59B | $1.41B | $1.46B | $1.42B | $1.40B | $1.30B | $1.38B | $1.32B | $1.32B | · | $1.28B | $1.24B | $1.25B | · | $1.28B | |
| Inventory | $233M | $225M | $189M | $186M | $187M | $189M | $188M | $184M | $182M | $181M | · | $184M | $184M | $190M | · | $183M | |
| Prepaid Expense | $319M | $361M | $361M | $333M | $273M | $294M | $351M | $299M | $245M | $251M | · | $207M | $188M | $195M | · | $171M | |
| Current Assets | $2.84B | $2.57B | $2.38B | $2.41B | $2.20B | $2.08B | $2.39B | $2.62B | $2.02B | $2.23B | · | $1.81B | $1.73B | $1.81B | · | $2.33B | |
| PP&E (Net) | $2.22B | $2.19B | $2.20B | $2.15B | $2.12B | $2.10B | $2.11B | $2.09B | $1.83B | $1.81B | · | $1.83B | $1.81B | $1.79B | · | $1.71B | |
| PP&E (Gross) | · | · | $6.18B | · | · | · | $5.77B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $3.97B | · | · | · | $3.66B | · | · | · | · | · | · | · | · | · | |
| Goodwill | $9.11B | $9.12B | $8.95B | $8.90B | $8.88B | $8.85B | $8.86B | $8.61B | $7.88B | $7.83B | $7.73B | $7.73B | $7.73B | $7.24B | $7.22B | $7.19B | |
| Intangibles | $1.67B | $1.72B | $1.64B | $1.66B | $1.71B | $1.73B | $1.76B | $1.72B | $1.20B | $1.19B | · | $1.22B | $1.25B | $1.08B | · | $1.11B | |
| Other Non-current Assets | $277M | $256M | $270M | $296M | $271M | $260M | $255M | $272M | $216M | $182M | · | $149M | $152M | $150M | · | $132M | |
| Total Assets | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Accounts Payable | $1.60B | $1.50B | $1.60B | $1.46B | $1.35B | $1.27B | $1.39B | $1.31B | $1.25B | $1.24B | · | $1.16B | $1.20B | $1.20B | · | $1.45B | |
| Accrued Liabilities | · | · | $338M | · | · | · | $306M | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $1.79B | $2.18B | $2.28B | $2.13B | $2.02B | $1.44B | $2.17B | $2.09B | $2.01B | $2.30B | · | $1.62B | $1.88B | $1.35B | · | $1.60B | |
| Capital Leases | $561M | $574M | $537M | $534M | $540M | $538M | $535M | $543M | $507M | $489M | · | $505M | $508M | $490M | · | $505M | |
| Other Non-current Liabilities | $1.06B | $1.02B | $957M | $982M | $890M | $917M | $938M | $891M | $811M | $817M | · | $874M | $901M | $809M | · | $787M | |
| Long-term Debt | $5.64B | · | $5.67B | · | · | · | $6.22B | $6.25B | · | · | · | · | · | · | · | · | |
| Total Debt | $5.64B | $503M | · | $504M | $504M | $1M | · | $6.25B | $606M | $906M | · | $304M | $518M | $2M | · | $2M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $10.37B | $10.15B | $9.99B | $9.84B | $9.68B | $9.49B | $9.36B | $9.22B | $9.08B | $8.94B | · | $8.71B | $8.57B | $8.41B | · | $8.26B | |
| Treasury Stock | $5.17B | $5.09B | $5.18B | $4.90B | $4.77B | $4.79B | $4.86B | $4.73B | $4.76B | $4.78B | · | $4.57B | $4.59B | $4.61B | · | $4.27B | |
| AOCI | $-62M | $-43M | $-27M | $-40M | $-16M | $-83M | $-88M | $-15M | $-19M | $-16M | · | $-20M | $-16M | $-18M | · | $-31M | |
| Stockholders' Equity | $7.52B | $7.37B | $7.17B | $7.26B | $7.23B | $6.93B | $6.78B | $6.81B | $6.62B | $6.43B | · | $6.42B | $6.25B | $6.05B | · | $6.24B | |
| Liabilities + Equity | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 110,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 114,000,000 |
Flusso di cassa 16
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $146M | $147M | $145M | $142M | $143M | $140M | $135M | $125M | $117M | $116M | $109M | $111M | $112M | $107M | $116M | $108M | |
| Stock-based Comp | $23M | $20M | $25M | $20M | $21M | $22M | $27M | $19M | $20M | $22M | $19M | $18M | $16M | $24M | $22M | $18M | |
| Deferred Tax | $-2M | $48M | $-13M | $110M | $1M | $7M | $34M | $15M | $-18M | $-18M | $-10M | $-23M | $-12M | $-4M | $-44M | $65M | |
| Amort. of Intangibles | $38M | $37M | $37M | $39M | $39M | $39M | $37M | $32M | $29M | $29M | $27M | $27M | $28M | $26M | $39M | $27M | |
| Restructuring | · | · | · | $6M | $1M | · | · | $7M | $8M | · | · | $1M | $1M | · | · | · | |
| Other Non-cash | · | $-189M | · | · | · | $-75M | · | · | · | $-160M | · | · | · | $-235M | · | · | |
| Operating Cash Flow | $597M | $278M | $465M | $563M | $544M | $314M | $464M | $356M | $360M | $154M | $527M | $207M | $444M | $94M | $334M | $502M | |
| CapEx | $138M | $114M | $158M | $144M | $108M | $117M | $123M | $106M | $92M | $104M | $72M | $105M | $104M | $127M | $147M | $118M | |
| Investing Cash Flow | $-134M | $-152M | $-191M | $-201M | $-124M | $-115M | $-502M | $-1.63B | $-200M | $-213M | $-114M | $-107M | $-682M | $-158M | $-174M | $-118M | |
| Stock Repurchased | · | · | $300M | $150M | · | · | $151M | · | · | · | $275M | $0 | $0 | $0 | $461M | $374M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Dividends Paid | $96M | $88M | $90M | $89M | $90M | $84M | $84M | $84M | $84M | $79M | $80M | $80M | $80M | $74M | $75M | $78M | |
| Financing Cash Flow | $-229M | $-152M | $-287M | $-247M | $-293M | $-561M | $-170M | $1.77B | $-363M | $-153M | $130M | $-83M | $189M | $-76M | $-545M | $-474M | |
| Net Change in Cash | $233M | $-27M | $-12M | $113M | $131M | $-361M | $-215M | $493M | $-203M | $-212M | $543M | $17M | $-49M | $-140M | $-385M | $-90M | |
| Free Cash Flow | · | $164M | · | · | · | $197M | · | · | · | $50M | · | · | · | $-33M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $13M | · | · | · | $-61M | · | · |
Redditività 7
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.1% | 13.8% | · | 13.7% | 15.9% | 13.1% | · | 13.3% | 14.8% | 12.7% | · | 14.9% | 14.9% | 13.1% | · | 15.8% | |
| Net Margin | 10.5% | 8.7% | · | 8.7% | 10.2% | 8.3% | · | 9.1% | 9.6% | 8.2% | · | 9.8% | 10.1% | 8.7% | · | 10.3% | |
| Pretax Margin | 13.5% | 11.5% | · | 11.7% | 13.9% | 10.4% | · | 11.9% | 13.1% | 11.2% | · | 13.0% | 13.6% | 11.9% | · | 14.1% | |
| EBITDA Margin | 19.9% | 18.9% | · | 18.8% | 21.0% | 18.3% | · | 18.3% | 19.7% | 17.6% | · | 19.7% | 19.7% | 17.7% | · | 20.1% | |
| ROA | 1.9% | 1.6% | · | 1.5% | 1.9% | 1.5% | · | 1.5% | 1.7% | 1.5% | · | 1.7% | 1.8% | 1.5% | · | 1.9% | |
| ROE | 4.3% | 3.5% | · | 3.5% | 4.1% | 3.3% | · | 3.4% | 3.6% | 3.1% | · | 3.5% | 3.7% | 3.2% | · | 4.0% | |
| ROIC | 2.7% | 4.0% | · | 3.8% | 4.2% | 3.9% | · | 2.0% | 3.8% | 3.1% | · | 3.9% | 3.9% | 3.9% | · | 4.8% |
Liquidità e Solvibilità 5
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.2 | · | 1.1 | 1.1 | 1.4 | · | 1.3 | 1.0 | 1.0 | · | 1.1 | 0.9 | 1.3 | · | 1.5 | |
| Quick Ratio | 1.3 | 0.9 | · | 0.9 | 0.9 | 1.1 | · | 1.0 | 0.8 | 0.8 | · | 0.9 | 0.7 | 1.1 | · | 1.2 | |
| Debt / Equity | 0.8 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.9 | 0.1 | 0.1 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | |
| LT Debt / Equity | 0.7 | · | · | · | · | · | · | 0.8 | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 7.6 | 6.1 | · | 8.3 | 8.9 | 8.2 | · | 10.6 |
Efficienza 3
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 9.6 | 9.4 | · | 10.1 | 9.9 | 9.7 | · | 9.1 | 8.7 | 8.6 | · | 8.4 | 8.3 | 8.1 | · | 8.3 | |
| Receivables Turnover | 2.0 | 1.9 | · | 2.0 | 2.0 | 1.9 | · | 1.9 | 1.9 | 1.8 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
Valutazione (TTM) 14
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.52B | $11.12B | · | $10.72B | $10.30B | $9.90B | · | $9.55B | $9.40B | $9.33B | · | $9.45B | $9.61B | $9.88B | · | $10.32B | |
| Net Income TTM | $1.10B | $999M | · | $973M | $957M | $869M | · | $874M | $883M | $856M | · | $918M | $927M | $1.05B | · | $1.35B | |
| Market Cap | $23.31B | $21.75B | · | $21.15B | $20.12B | $18.95B | · | $17.39B | $15.19B | $14.78B | · | $13.65B | $15.74B | $15.85B | · | $13.99B | |
| Enterprise Value | $28.33B | $21.86B | · | $21.23B | $20.30B | $18.76B | · | $22.88B | $15.53B | $15.21B | · | $13.81B | $16.13B | $15.67B | · | $13.29B | |
| P/E | 21.8 | 22.2 | · | 22.3 | 21.3 | 22.0 | · | 20.2 | 17.6 | 17.7 | · | 15.3 | 17.7 | 16.0 | · | 11.1 | |
| P/S | 2.0 | 2.0 | · | 2.0 | 2.0 | 1.9 | · | 1.8 | 1.6 | 1.6 | · | 1.4 | 1.6 | 1.6 | · | 1.4 | |
| P/B | 3.1 | 3.0 | · | 2.9 | 2.8 | 2.7 | · | 2.6 | 2.3 | 2.3 | · | 2.1 | 2.5 | 2.6 | · | 2.2 | |
| P / Cash Flow | · | 78.3 | · | · | · | 60.4 | · | · | · | 95.9 | · | · | · | 168.6 | · | · | |
| P / FCF | · | 132.6 | · | · | · | 96.2 | · | · | · | 295.5 | · | · | · | -480.2 | · | · | |
| EV / EBITDA | 46.8 | 40.0 | · | 40.2 | 34.9 | 38.6 | · | 50.3 | 32.9 | 36.6 | · | 30.5 | 35.1 | 38.0 | · | 26.6 | |
| EV / FCF | · | 133.3 | · | · | · | 95.2 | · | · | · | 304.1 | · | · | · | -474.9 | · | · | |
| EV / Revenue | 2.5 | 2.0 | · | 2.0 | 2.0 | 1.9 | · | 2.4 | 1.7 | 1.6 | · | 1.5 | 1.7 | 1.6 | · | 1.3 | |
| Earnings Yield | 4.6% | 4.5% | · | 4.5% | 4.7% | 4.5% | · | 5.0% | 5.7% | 5.6% | · | 6.5% | 5.7% | 6.2% | · | 9.0% | |
| Payout Ratio | · | 34.9% | · | · | · | 38.2% | · | · | · | 40.7% | · | · | · | 36.6% | · | · |
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
Conto Economico
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ricavi | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B |
| Margine Operativo % | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% |
| Utile netto | $992M | $871M | $854M | $946M | $2.00B |
| EPS Diluito | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
Stato Patrimoniale
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 |
| Rapporto corrente | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 |
Flusso di cassa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flusso di cassa libero | $1.36B | $909M | $864M | $1.31B | $1.83B |
Ultime notizie Notizie recenti che menzionano questa società
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
📊
Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Proprietari istituzionali (13F) 1.181 filer · $12.9B totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 121 (-13 vs trimestre precedente) | 63 (-19 vs trimestre precedente) | 408 (+62 vs trimestre precedente) | 330 (-21 vs trimestre precedente) | +21.9M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1.533.117.858 | 7.233.394 | 11,92% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.299.474.988 | 6.131.045 | 10,10% | Azioni |
| STATE STREET CORP | $1.169.252.484 | 5.516.643 | 9,09% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $584.135.885 | 2.767.754 | 4,54% | Azioni |
| EdgePoint Investment Group Inc. | $476.372.038 | 2.247.568 | 3,70% | Azioni |
| Grantham, Mayo, Van Otterloo & Co. LLC | $400.206.122 | 1.888.207 | 3,11% | Azioni |
| DIMENSIONAL FUND ADVISORS LP | $357.050.202 | 1.684.597 | 2,78% | Azioni |
| Davis Selected Advisers | $329.781.509 | 1.555.612 | 2,56% | Azioni |
| VICTORY CAPITAL MANAGEMENT INC | $311.037.928 | 1.467.506 | 2,42% | Azioni |
| NORGES BANK | $298.133.109 | 1.406.620 | 2,32% | Azioni |
| FMR LLC | $227.315.614 | 1.072.496 | 1,77% | Azioni |
| AMERICAN CENTURY COMPANIES INC | $173.422.135 | 818.220 | 1,35% | Azioni |
| M&G PLC | $168.677.800 | 795.650 | 1,31% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $131.756.386 | 621.639 | 1,02% | Azioni |
| ALLIANCEBERNSTEIN L.P. | $122.662.706 | 625.894 | 0,95% | Azioni |
| AMERIPRISE FINANCIAL INC | $109.652.758 | 517.352 | 0,85% | Azioni |
| Woodline Partners LP | $102.974.000 | 485.841 | 0,80% | Azioni |
| FIDUCIARY MANAGEMENT INC /WI/ | $102.489.906 | 483.557 | 0,80% | Azioni |
| Artemis Investment Management LLP | $99.175.856 | 467.921 | 0,77% | Azioni |
| CRAWFORD INVESTMENT COUNSEL INC | $97.514.204 | 460.081 | 0,76% | Azioni |
| PRINCIPAL FINANCIAL GROUP INC | $91.995.201 | 434.042 | 0,72% | Azioni |
| ENVESTNET ASSET MANAGEMENT INC | $90.834.224 | 428.564 | 0,71% | Azioni |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $86.608.697 | 407.302 | 0,67% | Azioni |
| BNP PARIBAS FINANCIAL MARKETS | $83.772.178 | 395.245 | 0,65% | Azioni |
| M.D. Sass, LLC | $76.397.960 | 360.453 | 0,59% | Azioni |
| Qube Research & Technologies Ltd | $72.783.206 | 343.398 | 0,57% | Azioni |
| MACKENZIE FINANCIAL CORP | $70.641.875 | 333.295 | 0,55% | Azioni |
| Advisors Capital Management, LLC | $69.429.626 | 327.575 | 0,54% | Azioni |
| Swiss National Bank | $65.683.305 | 309.900 | 0,51% | Azioni |
| Balyasny Asset Management L.P. | $58.364.883 | 275.371 | 0,45% | Azioni |
| Mitsubishi UFJ Asset Management Co., Ltd. | $56.877.630 | 268.354 | 0,44% | Azioni |
| RHUMBLINE ADVISERS | $56.744.612 | 267.727 | 0,44% | Azioni |
| BlackRock, Inc. | $55.976.419 | 264.102 | 0,44% | Azioni |
| Sumitomo Mitsui Trust Group, Inc. | $54.809.634 | 258.597 | 0,43% | Azioni |
| VANGUARD ASSET MANAGEMENT, Ltd | $53.654.295 | 253.146 | 0,42% | Azioni |
| Quantinno Capital Management LP | $53.607.358 | 252.924 | 0,42% | Azioni |
| RAYMOND JAMES FINANCIAL INC | $53.249.860 | 251.238 | 0,41% | Azioni |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $52.211.551 | 246.339 | 0,41% | Azioni |
| VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. | $51.484.139 | 242.907 | 0,40% | Azioni |
| Clark Capital Management Group, Inc. | $51.259.362 | 241.846 | 0,40% | Azioni |
| Vanguard Global Advisers, LLC | $51.025.267 | 240.742 | 0,40% | Azioni |
| Legal & General Group Plc | $50.185.731 | 236.781 | 0,39% | Azioni |
| FIL Ltd | $49.419.958 | 233.168 | 0,38% | Azioni |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $49.341.000 | 232.797 | 0,38% | Azioni |
| Eurizon Capital SGR S.p.A. | $47.173.414 | 222.564 | 0,37% | Azioni |
| BARCLAYS PLC | $45.003.978 | 212.333 | 0,35% | Azioni |
| PFA Pension, Forsikringsaktieselskab | $43.579.660 | 205.613 | 0,34% | Azioni |
| Integral Health Asset Management, LLC | $42.390.000 | 200.000 | 0,33% | Azioni |
| California Public Employees Retirement System | $41.574.204 | 196.151 | 0,32% | Azioni |
| CONNING INC. | $39.578.271 | 186.734 | 0,31% | Azioni |
| SEB Asset Management AB | $38.766.863 | 182.906 | 0,30% | Azioni |
| BANK OF MONTREAL /CAN/ | $38.512.587 | 181.706 | 0,30% | Azioni |
| GOLDMAN SACHS GROUP INC | $38.322.295 | 180.808 | 0,30% | Azioni |
| Boston Partners | $35.509.632 | 167.514 | 0,28% | Azioni |
| Focus Partners Wealth | $34.616.947 | 163.327 | 0,27% | Azioni |
| STOREBRAND ASSET MANAGEMENT AS | $34.117.592 | 160.970 | 0,27% | Azioni |
| COOKSON PEIRCE & CO INC | $32.977.089 | 155.589 | 0,26% | Azioni |
| UBS Group AG | $32.934.699 | 155.389 | 0,26% | Azioni |
| BRAUN STACEY ASSOCIATES INC | $32.724.232 | 154.396 | 0,25% | Azioni |
| Willis Investment Counsel | $32.110.425 | 151.500 | 0,25% | Azioni |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $31.795.403 | 162.238 | 0,25% | Azioni |
| LPL Financial LLC | $30.325.576 | 143.079 | 0,24% | Azioni |
| APG Asset Management N.V. | $27.869.580 | 150.334 | 0,22% | Azioni |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $26.893.912 | 126.888 | 0,21% | Azioni |
| &PARTNERS | $26.382.365 | 124.363 | 0,21% | Azioni |
| JANE STREET GROUP, LLC | $25.942.680 | 122.400 | 0,20% | Opzione Call |
| BANK OF AMERICA CORP /DE/ | $25.492.499 | 120.276 | 0,20% | Azioni |
| Candriam S.C.A. | $25.459.925 | 120.238 | 0,20% | Azioni |
| Squarepoint Ops LLC | $24.974.280 | 117.831 | 0,19% | Azioni |
| Gotham Asset Management, LLC | $24.911.119 | 117.533 | 0,19% | Azioni |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $24.607.896 | 116.373 | 0,19% | Azioni |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $24.569.456 | 115.921 | 0,19% | Azioni |
| Robeco Institutional Asset Management B.V. | $23.854.123 | 112.546 | 0,19% | Azioni |
| AEGON ASSET MANAGEMENT UK Plc | $22.866.862 | 107.888 | 0,18% | Azioni |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | $22.670.926 | 106.964 | 0,18% | Azioni |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $22.530.921 | 106.303 | 0,18% | Azioni |
| MERCER GLOBAL ADVISORS INC /ADV | $22.064.117 | 104.101 | 0,17% | Azioni |
| Moran Wealth Management, LLC | $22.053.609 | 104.051 | 0,17% | Azioni |
| ABN AMRO Bank N.V. | $21.523.733 | 101.667 | 0,17% | Azioni |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $21.496.202 | 123.876 | 0,17% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $21.322.170 | 100.600 | 0,17% | Opzione Call |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $21.146.252 | 99.770 | 0,16% | Azioni |
| AVIVA PLC | $20.378.569 | 96.148 | 0,16% | Azioni |
| SCHWARTZ INVESTMENT COUNSEL INC | $20.326.005 | 95.900 | 0,16% | Azioni |
| Boston Common Asset Management, LLC | $20.282.767 | 95.696 | 0,16% | Azioni |
| CAPTRUST FINANCIAL ADVISORS | $20.146.790 | 95.054 | 0,16% | Azioni |
| Midwest Trust Co | $20.113.207 | 94.896 | 0,16% | Azioni |
| LAZARD ASSET MANAGEMENT LLC | $20.035.210 | 94.528 | 0,16% | Azioni |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | $19.842.759 | 93.620 | 0,15% | Azioni |
| BLAIR WILLIAM & CO/IL | $19.773.115 | 93.291 | 0,15% | Azioni |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $19.613.005 | 92.536 | 0,15% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19.160.280 | 90.400 | 0,15% | Opzione Put |
| CITADEL ADVISORS LLC | $18.821.160 | 88.800 | 0,15% | Opzione Call |
| WELLINGTON MANAGEMENT GROUP LLP | $17.507.282 | 82.601 | 0,14% | Azioni |
| Foundry Partners, LLC | $17.338.432 | 102.473 | 0,13% | Azioni |
| MARSHALL WACE, LLP | $17.187.874 | 81.094 | 0,13% | Azioni |
| Coho Partners, Ltd. | $16.981.317 | 89.103 | 0,13% | Azioni |
| Copeland Capital Management, LLC | $16.902.800 | 79.749 | 0,13% | Azioni |
| CIBC Asset Management Inc | $16.674.318 | 78.671 | 0,13% | Azioni |
| Mitsubishi UFJ Trust & Banking Corp | $16.558.594 | 78.125 | 0,13% | Azioni |
Insider aziendali 53 insider · 26 dirigenti · 26 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| E. J. Davis | CEO and President | 01 Giugno 2026 S | 132.423 | 0 | 5 | $-14.656.302 |
| Surya N Mohapatra | Chairman, President & CEO | 30 Aprile 2012 F | 243.713 | 0 | 0 | $0 |
| Sam Samad | Executive Vice President & CFO | 22 Luglio 2026 A | 33.478 | 0 | 0 | $0 |
| Mark Guinan | Executive Vice President & CFO | 07 Marzo 2022 F | 98.981 | 0 | 0 | $0 |
| Robert Hagemann | SVP & Chief Financial Officer | 05 Marzo 2013 F | 126.722 | 0 | 0 | $0 |
| Mark E Delaney | SVP & Chief Commercial Officer | 28 Luglio 2026 S | 10.335 | 0 | 1 | $-376.288 |
| Karthik Kuppusamy | SVP, Clinical Solutions | 22 Luglio 2026 L | 13.557 | 0 | 2 | $-2.167.772 |
| Patrick Plewman | SVP for Diagnostic Services | 22 Luglio 2026 L | 15.293 | 0 | 5 | $-3.023.678 |
| Catherine T. Doherty | EVP, Regional Businesses | 05 Marzo 2026 S | 67.122 | 0 | 7 | $-6.671.228 |
| Michael E Prevoznik | SVP & General Counsel | 05 Marzo 2026 S | 37.557 | 0 | 7 | $-6.505.199 |
| Michael J Deppe | SVP, Corp. Controller & CAO | 04 Marzo 2026 F | 35.196 | 0 | 0 | $0 |
| Mark A Gardner | SVP of Molecular Gen & Oncol | 24 Settembre 2024 F | 4.673 | 0 | 0 | $0 |
| Manner Carrie Eglinton | SVP, Advanced Diagnostics | 07 Marzo 2022 F | 48.391 | 0 | 0 | $0 |
| Manuel O. Mendez | SVP & Chief Commercial Officer | 17 Febbraio 2021 A | 29.045 | 0 | 0 | $0 |
| Robert A Klug | VP, Corporate Controller | 01 Marzo 2019 F | 6.261 | 0 | 0 | $0 |
| Jon R Cohen | SVP & Group Exec. Diag. Sol. | 08 Marzo 2018 M | 31.757 | 0 | 0 | $0 |
| Everett Cunningham | SVP, Commercial | 01 Marzo 2018 G | 37.760 | 0 | 0 | $0 |
| Thomas F Bongiorno | VP and Corporate Controller | 02 Marzo 2015 F | 11.837 | 0 | 0 | $0 |
| John B. Haydon | SVP, Operations | 13 Febbraio 2014 A | 19.890 | 0 | 0 | $0 |
| Kathy Ordonez | SVP, Diagnostic Solutions | 31 Marzo 2013 F | 9.569 | 0 | 0 | $0 |
| Joan Elizabeth Miller | SVP-Oncology & Neurology Srvcs | 29 Febbraio 2012 F | 89.232 | 0 | 0 | $0 |
| Wayne R. Simmons | Vice President, Operations | 16 Giugno 2011 M | 47.150 | 0 | 0 | $0 |
| Robert E Peters | VP, Sales & Marketing | 12 Febbraio 2007 A | 12.974 | 0 | 0 | $0 |
| David M Zewe | SVP, Diagnostic Testing Ops | 12 Febbraio 2007 A | 31.079 | 0 | 0 | $0 |
| GRANT THOMAS W II | Sr VP, Ins. & Employer Serv. | 12 Febbraio 2007 A | — | 0 | 0 | $0 |
| Gerald C Marrone | SVP, Administration | 28 Febbraio 2004 F | 49.609 | 0 | 0 | $0 |
| Wright Lassiter III | Direttore | 22 Luglio 2026 L | 10.323 | 0 | 0 | $0 |
| Vicky B Gregg | Direttore | 22 Luglio 2026 A | 18.386 | 0 | 1 | $-239.700 |
| Robert B Carter | Direttore | 22 Luglio 2026 L | 3.864 | 0 | 0 | $0 |
| Timothy L Main | Direttore | 22 Luglio 2026 L | 22.460 | 0 | 0 | $0 |
| Timothy C Wentworth | Direttore | 01 Luglio 2026 A | 1.358 | 0 | 0 | $0 |
| Timothy M Ring | Direttore | 20 Maggio 2026 A | 31.140 | 0 | 0 | $0 |
| Gary M Pfeiffer | Direttore | 20 Maggio 2026 A | 31.005 | 0 | 1 | $-270.317 |
| Luis Diaz | Direttore | 15 Maggio 2025 A | 4.054 | 0 | 0 | $0 |
| Tracey Doi | Direttore | 15 Maggio 2025 A | 6.490 | 0 | 0 | $0 |
| Gail R Wilensky | Direttore | 17 Maggio 2023 A | 20.506 | 0 | 0 | $0 |
| Stephen H Rusckowski | Direttore | 06 Marzo 2023 F | 389.597 | 0 | 0 | $0 |
| Helen Torley | Direttore | 25 Maggio 2021 A | 6.260 | 0 | 0 | $0 |
| Daniel Stanzione | Direttore | 23 Novembre 2020 S | 28.349 | 0 | 0 | $0 |
| Jenne K Britell | Direttore | 04 Giugno 2018 G | 14.479 | 0 | 0 | $0 |
| Jeffrey M Leiden | Direttore | 29 Maggio 2018 S | 6.000 | 0 | 0 | $0 |
| John B Ziegler | Direttore | 22 Febbraio 2017 S | 16.557 | 0 | 0 | $0 |
| John C Baldwin MD | Direttore | 12 Agosto 2015 S | 12.949 | 0 | 0 | $0 |
| William F Buehler | Direttore | 12 Febbraio 2014 M | 26.225 | 0 | 0 | $0 |
| GSK plc | Direttore | 31 Gennaio 2011 S | 0 | 0 | 0 | $0 |
| Rosanne Haggerty | Direttore | 06 Maggio 2010 A | 9.334 | 0 | 0 | $0 |
| William R Grant | Direttore | 01 Aprile 2007 A | 3.334 | 0 | 0 | $0 |
| James F Flaherty III | Direttore | 04 Maggio 2006 A | 1.667 | 0 | 0 | $0 |
| Kenneth D Brody | Direttore | 28 Aprile 2004 S | 0 | 0 | 0 | $0 |
| Mary A Cirillo | Direttore | 01 Aprile 2004 A | 2.627 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Attivisti e proprietari del 5%+ 13 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated | 18 Maggio 2011 | — | Deposito iniziale | M&A / vendita | SEC |
| Persona segnalante non divulgata | 01 Febbraio 2011 | — | Deposito iniziale | Investimento passivo | SEC |
| Persona segnalante non divulgata | 20 Marzo 2009 | — | Deposito iniziale | — | SEC |
| GlaxoSmithKline plc ×2 depositi | 18 Settembre 2008 | — | Deposito iniziale | — | SEC |
| Persona segnalante non divulgata | 16 Febbraio 2007 | — | Deposito iniziale | — | SEC |
| Quest Diagnostics Incorporated - (FEIN No. ×2 depositi | 19 Gennaio 2006 | — | Deposito iniziale | — | SEC |
| Persona segnalante non divulgata | 15 Dicembre 2004 | — | Deposito iniziale | — | SEC |
| Persona segnalante non divulgata | 29 Giugno 2004 | — | Deposito iniziale | — | SEC |
| Persona segnalante non divulgata | 24 Giugno 2002 | — | Deposito iniziale | M&A / vendita | SEC |
| Persona segnalante non divulgata | 22 Maggio 2002 | — | Deposito iniziale | — | SEC |
| Persona segnalante non divulgata | 12 Aprile 2002 | — | Deposito iniziale | M&A / vendita | SEC |
| IRS Identification Nos. of Above Persons (entities only) Quest Diagnostics Ventures LLC - (FEIN No., Quest Diagnostics Incorporated - (FEIN No. ×3 depositi | 01 Novembre 2001 | — | Deposito iniziale | M&A / vendita | SEC |
| Persona segnalante non divulgata | 14 Maggio 2001 | — | Deposito iniziale | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Proprietà ETF Posseduti da 183 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| IHF · iShares Trust | 3,91% | 203.179 SH | 08 Agosto 2026 | Giornaliero |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,77% | 58.107 SH | 08 Agosto 2026 | Giornaliero |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,29% | 57.932 NS | 30 Aprile 2026 | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 1,22% | 9.813 SH | 08 Agosto 2026 | Giornaliero |
| TMFX · RBB Fund, Inc. | 1,05% | 1.724 NS | 31 Maggio 2026 | N-PORT |
| ANEW · ProShares Trust | 0,92% | 364 NS | 31 Maggio 2026 | N-PORT |
| QLTY · GMO ETF Trust | 0,85% | 196.208 NS | 31 Maggio 2026 | N-PORT |
| ALTL · Pacer Funds Trust | 0,82% | 4.047 NS | 30 Aprile 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,80% | 635 NS | 30 Aprile 2026 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,76% | 4.201 SH | 08 Agosto 2026 | Giornaliero |
| QLV · FlexShares Trust | 0,74% | 6.461 NS | 30 Aprile 2026 | N-PORT |
| GDOC · Goldman Sachs ETF Trust | 0,72% | 741 NS | 31 Maggio 2026 | N-PORT |
| ESMV · iShares Trust | 0,72% | 236 SH | 08 Agosto 2026 | Giornaliero |
| HUSV · First Trust Exchange-Traded Fund III | 0,52% | 1.956 NS | 30 Aprile 2026 | N-PORT |
| ITAN · EA Series Trust | 0,46% | 2.110 NS | 29 Maggio 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 0,44% | 1.055 NS | 30 Aprile 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0,44% | 409.814 NS | 30 Aprile 2026 | N-PORT |
| IYH · iShares Trust | 0,43% | 66.179 SH | 08 Agosto 2026 | Giornaliero |
| SIXL · EXCHANGE TRADED CONCEPTS TRUST | 0,41% | 3.999 NS | 31 Maggio 2026 | N-PORT |
| VOE · VANGUARD INDEX FUNDS | 0,40% | 711.079 SH | 08 Agosto 2026 | Giornaliero |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,38% | 8.682 NS | 30 Aprile 2026 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,37% | 8.368 NS | 30 Aprile 2026 | N-PORT |
| IMCV · iShares Trust | 0,37% | 17.734 SH | 08 Agosto 2026 | Giornaliero |
| FHLC · FIDELITY COVINGTON TRUST | 0,35% | 51.278 NS | 30 Aprile 2026 | N-PORT |
| SUSA · iShares Trust | 0,35% | 60.308 SH | 08 Agosto 2026 | Giornaliero |
| FTA · First Trust Exchange-Traded AlphaDE… | 0,34% | 23.030 NS | 30 Aprile 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,34% | 330.273 SH | 08 Agosto 2026 | Giornaliero |
| IXJ · iShares Trust | 0,33% | 58.047 SH | 08 Agosto 2026 | Giornaliero |
| RXL · ProShares Trust | 0,31% | 1.147 NS | 31 Maggio 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,31% | 2.194 NS | 30 Aprile 2026 | N-PORT |
| GNOM · Global X Funds | 0,28% | 789 NS | 31 Maggio 2026 | N-PORT |
| DFLV · Dimensional ETF Trust | 0,26% | 79.983 NS | 30 Aprile 2026 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,26% | 7.703.000 | 08 Agosto 2026 | Giornaliero |
| IWS · iShares Trust | 0,25% | 166.611 SH | 08 Agosto 2026 | Giornaliero |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,24% | 18.806 NS | 30 Aprile 2026 | N-PORT |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0,24% | 8.995 NS | 30 Aprile 2026 | N-PORT |
| EQIN · Columbia ETF Trust I | 0,23% | 3.340 NS | 30 Aprile 2026 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0,23% | 26.229 NS | 30 Aprile 2026 | N-PORT |
| SIZE · iShares Trust | 0,23% | 4.242 SH | 08 Agosto 2026 | Giornaliero |
| VO · VANGUARD INDEX FUNDS | 0,23% | 2.398.948 SH | 08 Agosto 2026 | Giornaliero |
| BFOR · ALPS ETF Trust | 0,22% | 2.467 NS | 31 Maggio 2026 | N-PORT |
| EUSA · iShares, Inc. | 0,22% | 17.880 SH | 08 Agosto 2026 | Giornaliero |
| DFVE · DoubleLine ETF Trust | 0,22% | 307 NS | 31 Marzo 2026 | N-PORT |
| VFMV · VANGUARD WELLINGTON FUND | 0,22% | 4.307 SH | 08 Agosto 2026 | Giornaliero |
| RSP · Invesco Exchange-Traded Fund Trust | 0,22% | 910.753 SH | 08 Agosto 2026 | Giornaliero |
| GSEW · Goldman Sachs ETF Trust | 0,20% | 18.310 NS | 31 Maggio 2026 | N-PORT |
| ACWV · iShares, Inc. | 0,20% | 28.277 SH | 08 Agosto 2026 | Giornaliero |
| DEUS · DBX ETF Trust | 0,20% | 2.734 NS | 29 Maggio 2026 | N-PORT |
| IWR · iShares Trust | 0,19% | 449.590 SH | 08 Agosto 2026 | Giornaliero |
| IMCB · iShares Trust | 0,18% | 12.737 SH | 08 Agosto 2026 | Giornaliero |